检索结果 - Ho Yeong Lim
- Showing 1 - 20 results of 80
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
-
7
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study 由 Jordi Bruix, Won Young Tak, Antonio Gasbarrini, Armando Santoro, M. Colombo, Ho-Yeong Lim, Vincenzo Mazzaferro, Reiner Wiest, María Reig, Thierry André, Luigi Bolondi
出版 2013Artigo -
8
-
9
-
10
-
11
Impact of epidermal growth factor receptor (EGFR) kinase mutations, <i>EGFR</i> gene amplifications, and <i>KRAS</i> mutations on survival of pancreatic adenocarcinoma 由 Jeeyun Lee, Kee‐Taek Jang, Chang‐Seok Ki, Taekyu Lim, Young Suk Park, Ho Yeong Lim, Dongwook Choi, Won Ki Kang, Keunchil Park, Joon Oh Park
出版 2007Artigo -
12
Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy 由 Seung Tae Kim, Samuel J. Klempner, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Kyoung-Mee Kim, Jeeyun Lee
出版 2017Artigo -
13
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma 由 Changhoon Yoo, Joong‐Won Park, Yoon Jun Kim, Do Young Kim, Su Jong Yu, Tae Seop Lim, Su Jin Lee, Baek‐Yeol Ryoo, Ho Yeong Lim
出版 2018Artigo -
14
Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma 由 Chan Kim, Hannah Yang, Il Hwan Kim, Beodeul Kang, Hyeyeong Kim, Hyunho Kim, Won Suk Lee, Sanghoon Jung, Ho Yeong Lim, Jaekyung Cheon, Hong Jae Chon
出版 2022Artigo -
15
-
16
Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcino... 由 Shukui Qin, Yuxian Bai, Ho Yeong Lim, Sumitra Thongprasert, Yee Chao, Jia Fan, Tsai‐Shen Yang, Vajarabhongsa Bhudhisawasdi, Won Ki Kang, Yu Zhou, Jee Hyun Lee, Yan Sun
出版 2013Artigo -
17
Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma 由 Thomas E. Hutson, Bernard Escudier, Emilio Esteban, Georg A. Bjarnason, Ho Yeong Lim, K. Pittman, P. Senico, Andreas G. Niethammer, Dongrui R. Lu, Hariharan Subramanian, Robert J. Motzer
出版 2013Artigo -
18
Temsirolimus vs Sorafenib As Second Line Therapy in Metastatic Renal Cell Carcinoma: Results from the Intorsect Trial 由 Thomas E. Hutson, Bernard Escudier, E. Barrado, Georg A. Bjarnason, Ho Yeong Lim, K. Pittman, P. Senico, Andreas G. Niethammer, Dongrui R. Lu, Seetharaman Hariharan, Robert J. Motzer
出版 2012Artigo -
19
-
20
相关主题
Medicine
Internal medicine
Oncology
Cancer
Gastroenterology
Hepatocellular carcinoma
Sorafenib
Surgery
Chemotherapy
Clinical endpoint
Biology
Colorectal cancer
Adverse effect
Immunotherapy
Pathology
Randomized controlled trial
Confidence interval
Cancer research
Alternative medicine
Biochemistry
Nivolumab
Placebo
Gene
Hazard ratio
Phases of clinical research
Sunitinib
Renal cell carcinoma
Urology
Clinical trial
Bevacizumab